● Recruiting

Phase III Study of TY-9591 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer (FLETEO)

Condition: NSCLC · EGFR Activating Mutation · Sponsor: TYK Medicines, Inc

PhasePhase 3

Planned participants680

Who can joinAll sexes, 18 Years to 80 Years

Healthy volunteersNo

About this study

To assess the efficacy and safety of TY-9591 versus Osimertinib in patients with locally advanced or Metastatic Non Small Cell Lung Cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Baohui Han, MD · 18930858216 · 18930858216@163.com

Always discuss trial participation with your own doctor first.

Locations (2)

Hunan Provincial Tumor Hospital	Changsha, Hunan, China	Recruiting
Shanghai Chest Hospital	Shanghai, Shanghai Municipality, China	Recruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05382728